Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ptc Therapeutics (PTCT) Net Margin (2016 - 2025)

Ptc Therapeutics (PTCT) has 14 years of Net Margin data on record, last reported at 251.47% in Q4 2025.

  • For Q4 2025, Net Margin rose 28238.0% year-over-year to 251.47%; the TTM value through Dec 2025 reached 68.56%, up 15718.0%, while the annual FY2025 figure was 71.88%, 11691.0% up from the prior year.
  • Net Margin reached 251.47% in Q4 2025 per PTCT's latest filing, up from 10.94% in the prior quarter.
  • Across five years, Net Margin topped out at 251.47% in Q4 2025 and bottomed at 109.07% in Q1 2021.
  • Average Net Margin over 5 years is 40.22%, with a median of 58.63% recorded in 2024.
  • The widest YoY moves for Net Margin: up 28238bps in 2025, down -8692bps in 2025.
  • A 5-year view of Net Margin shows it stood at 86.71% in 2021, then fell by -18bps to 102.08% in 2022, then soared by 50bps to 50.74% in 2023, then soared by 39bps to 30.91% in 2024, then skyrocketed by 914bps to 251.47% in 2025.
  • Per Business Quant database, its latest 3 readings for Net Margin were 251.47% in Q4 2025, 10.94% in Q3 2025, and 39.72% in Q2 2025.